drugset / Trial / NCT05164250

Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

NCT05164250

Expanded access Approved for marketing Regeneron Pharmaceuticals

Summary

Provide Compassionate Use' of REGN5458 for Patients with Relapsed or Refractory Multiple Myeloma

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Background Linvoseltamab Monoclonal antibody

Indications